COPENHAGEN (www.healthproductportal.com) - Danish cluster Novo Nordisk's diabetes drug Victoza contains a forty three % probability of being approved as an obesity treatment within the us, in step with a Reuters poll that found Danish bank analysts had the best expectations.
Novo Nordisk, the world's biggest insulin producer, is in part 3 of studies to use Victoza to treat obesity and expects the treatment to be launched within the us late in of 2014 or early 2015.
Liraglutide, an energetic ingredient in Victoza, has shown it may be effective in serving to obese folks losing weight.
A survey of ten analysts found a median forecast of a forty three % probability of Victoza being approved by the U.S. Food and Drug Administration as an obesity treatment, with analysts from international banks additional skeptical than Danish peers.
Five analysts from international banks created a thirty two % average forecast, compared with a forecast for 5} % from five analysts from Danish banks.
United Nations knowledge showed rates of obesity doubled in each region of the globe between 1980 and 2008 with 0.5 a billion folks - or twelve % of the world's population - currently thought of obese.
The highest obesity levels are within the Americas, where twenty six % of adults are obese, the Geneva-based World Health Organisation's (WHO) annual report on world health showed, adding that one in ten adults worldwide has diabetes.
Diabetes puts sufferers in danger of heart disease, kidney failure and blindness and might carry obesity as a facet result.
While the FDA has not approved any obesity medication since 1999, Novo Nordisk rivals Vivus and Arena prescribed drugs are given positive recommendations by a panel to the FDA on their obesity candidates.
The FDA is wanting into cardiovascular safety in relation to obesity medication which can cause weight loss, however at the price of rising heart rate.